

Zydus receives final approval from the USFDA for Baclofen Tablets

Ahmedabad, 27 November, 2018

Zydus Cadila has received the final approval from the USFDA to market Baclofen Tablets (US RLD- Lioresal[®]) 10 mg and 20 mg. It will be manufactured at the group's formulations manufacturing facility at Baddi. Baclofen is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury/disease. It works by helping to relax the muscles.

The group now has 234 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
